[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
October 2016

Public Health Policy Lessons From Oklahoma

Author Affiliations
  • 1Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland
  • 2Department of Ophthalmology, University of Maryland, Baltimore

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Ophthalmol. 2016;134(10):1102-1103. doi:10.1001/jamaophthalmol.2016.2573

Laser trabeculoplasty (LTP) was popularized in 19791 in eyes receiving maximal medical therapy. Various prospective clinical trials sponsored by the National Institutes of Health have since better defined its usefulness in early and advanced glaucoma. Today, the American Academy of Ophthalmology Primary Open Angle Glaucoma Preferred Practice Pattern finds that argon LTP and selective LTP have comparable intraocular pressure (IOP) lowering efficacy and safety profiles, but additional LTP (regardless of the laser type) has a decreased rate of success and an increased complication profile, including permanent IOP increase.2